Literature DB >> 8210615

Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis.

M Ip1, D Shum, I Lauder, W K Lam, S Y So.   

Abstract

We studied the changes in sputum neutrophil chemotactic activity (NCA) and elastolytic activity (EA) in acute exacerbations of bronchiectasis before and after treatment with oral antibiotics. Twelve patients who chronically produced sputum were assessed in the stable state, and when they subsequently developed symptoms of acute exacerbations, prior to initiation of antibiotics, during 2 weeks of antibiotics, and at 2 and 6 weeks after stopping antibiotics. NCA was measured using modified Boyden's technique with multiwell chemotaxis chamber, and EA with N-succinyl-trialanine-p-nitroanilide as elastase substrate. All 12 patients had NCA (49.3 +/- 8.69% FMLP response) and EA (50.5 +/- 17.1 mU per 100 microliters) in their sputum in the stable state. At acute exacerbation, there was significant increase in NCA (P < 0.001) and EA (P < 0.05). All responded clinically after 1 week of antibiotics, and this was associated with a decrease in NCA and EA back to the levels in stable state. A further week of antibiotics did not result in further decline of NCA or EA. Three patients had another acute exacerbation clinically between 2-6 weeks after stopping antibiotics and their NCA and EA rose again. In the other nine patients, both NCA and EA at 2 and 6 weeks post-treatment were similar to pre-exacerbation levels. Our findings suggest that short course antibiotics effectively control the upsurge in inflammatory activity in acute exacerbations, but has little effect on chronic airway inflammation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8210615     DOI: 10.1016/0954-6111(93)90072-8

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis.

Authors:  M Gaga; A M Bentley; M Humbert; J Barkans; F O'Brien; C G Wathen; A B Kay; S R Durham
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 2.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

3.  Critical care admission trends and outcomes in individuals with bronchiectasis in the UK.

Authors:  Vidya Navaratnam; Colin R Muirhead; Richard B Hubbard; Anthony De Soyza
Journal:  QJM       Date:  2015-11-17

Review 4.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

Review 5.  Neurological and Sleep Disturbances in Bronchiectasis.

Authors:  Chun Seng Phua; Tissa Wijeratne; Conroy Wong; Lata Jayaram
Journal:  J Clin Med       Date:  2017-11-30       Impact factor: 4.241

Review 6.  Neutrophil elastase in bronchiectasis.

Authors:  Andrea Gramegna; Francesco Amati; Leonardo Terranova; Giovanni Sotgiu; Paolo Tarsia; Daniela Miglietta; Maria Adelaide Calderazzo; Stefano Aliberti; Francesco Blasi
Journal:  Respir Res       Date:  2017-12-19

7.  Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Robert S Ware; Catherine A Byrnes; Peter S Morris; I Brent Masters; Gabrielle B McCallum; Michael J Binks; Heidi Smith-Vaughan; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; André Schultz; Mark Chatfield; Paul J Torzillo; Anne B Chang
Journal:  Lancet Respir Med       Date:  2019-08-16       Impact factor: 30.700

Review 8.  Protease-Antiprotease Imbalance in Bronchiectasis.

Authors:  Martina Oriano; Francesco Amati; Andrea Gramegna; Anthony De Soyza; Marco Mantero; Oriol Sibila; Sanjay H Chotirmall; Antonio Voza; Paola Marchisio; Francesco Blasi; Stefano Aliberti
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

9.  Bronchiectasis and the risk of cardiovascular disease: a population-based study.

Authors:  Vidya Navaratnam; Elizabeth R C Millett; John R Hurst; Sara L Thomas; Liam Smeeth; Richard B Hubbard; Jeremy Brown; Jennifer K Quint
Journal:  Thorax       Date:  2016-08-29       Impact factor: 9.139

10.  Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Catherine A Byrnes; Peter S Morris; I Brent Masters; Robert S Ware; Gabrielle B McCallum; Michael J Binks; Julie M Marchant; Peter van Asperen; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; Helen Petsky; Paul J Torzillo; Anne B Chang
Journal:  Lancet       Date:  2018-09-18       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.